Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT in Severe Unexplained Atherosclerosis
NCT04410003Phase 1Recruiting
- Sponsor
- Western University
- Start
- Jun 2020
- Primary completion
- Jul 2025
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in atherosclerosis comparing FMT with Placebo (2 arms). Primary endpoints: Changes in plasma levels of metabolites of the intestinal microbiome at 12 months and Metagenomic changes of the intestinal microbiome at 12 months. Started Jun 2020; status: recruiting.
02
Drugs
fecal microbiome transplant
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT04410003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410003.